circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
== Binding change mechanism == The binding change mechanism, proposed by Paul Boyer and John E. Walker, who were awarded the Nobel Prize in Chemistry in 1997, suggests that ATP synthesis is linked to a conformational change in ATP synthase. This change is triggered by the rotation of the gamma subunit. ATP synthesis can be achieved through several mechanisms. The first mechanism postulates that the free energy of the proton gradient is utilized to alter the conformation of polypeptide molecules in the ATP synthesis active centers. The second mechanism suggests that the change in the conformational state is also produced by the transformation of mechanical energy into chemical energy using biological mechanoemission, a process in which energy or particles (e.g., photons or ions) are emitted from a mitochondrion when it is mechanically stimulated.
Sometimes called "non-genetic EDS", hypermobility spectrum disorder can have the same signs as hEDS, but be caused not by a heritable genetic mutation but by problems in fetal development, such as pre-natal exposure to toxins like agricultural chemicals, drugs, or alcohol. Fetal Alcohol Spectrum Disorders affect at least 1 in 20 people in the U.S., and joint hypermobility with other symptoms is common.
Despite most known prohormones having now been banned, novel compounds of this type or older compounds which are simply not listed as ingredients, are still sometimes found in over-the-counter pre-workout products, and are a frequent cause of inadvertent drug testing failures by athletes in competition. Selective androgen receptor modulators (SARMs) such as enobosarm and ligandrol are also sometimes found as ingredients in pre-workout supplement blends, and again when present are often not accurately declared on the ingredients listing.
Helium liquifies when cooled below 4.2 K (−268.95 °C; −452.11 °F) at atmospheric pressure. Unlike any other element, however, helium remains liquid down to a temperature of absolute zero. This is a direct effect of quantum mechanics: specifically, the zero point energy of the system is too high to allow freezing. Pressures above about 2.5 MPa (25 atm) are required to freeze it. There are two liquid phases: Helium I is a conventional liquid, and Helium II, which occurs at a lower temperature, is a superfluid.
Xanthoria parietina hosts a diverse array of lichenicolous fungi—fungi that live on lichens. As of 2017, at least 41 species of lichenicolous fungi have been reported on X. parietina, including both obligate parasites and facultative colonizers. Examples include Athelia arachnoidea, Catillaria nigroclavata, and Capronia suijae. While some of these fungi may be pathogenic, others colonize the lichen without causing obvious damage to the thallus. In some cases, multiple lichenicolous and saprotrophic fungi can form complex communities on decaying thalli of X. parietina. One study in Austria documented ten different fungal species simultaneously colonizing damaged lichen thalli. The most visually apparent was Xanthoriicola physciae, while the dematiaceous hyphomycete Cladosporium macrocarpum was the most abundant colonizer, covering large areas of the thallus and apothecia with dark cottony filaments. This fungus causes visible discoloration and unevenness of the apothecial discs before eventually destroying the lichen structure. Other notable parasites included Lichenoconium xanthoriae, Lichenodiplis poeltii, and Pyrenochaeta xanthoriae. The highly destructive Marchandiomyces aurantiacus forms distinctive pale orange crumbles on the lichen surface, ultimately shrinking the thallus to a bleached, fragile film that clings to the substrate before complete decay.
Sources: en.wikipedia.org
This period is also marked by the appearance of the self-portraits of painters in long tunics and highboots armed with short daggers, such as the painter of the Cave of the Statues or the several painters of the "Cave of the Painters", with often their own identifying labels in Sanskrit. The clothing style and type of these painters has often been described as Sasanian, but has recently been proposed as being rather Hephthalite, due to the similarities with the Hephthalite figures in Dilberjin Tepe, Balalyk Tepe or Bamiyan, and because the Hepthalites did control the Tarim Basin for nearly a century around this time period.
Dysphoria and apathy (due to dopamine receptor blockade) Sedation (particularly common with asenapine, clozapine, olanzapine, quetiapine, chlorpromazine and zotepine) Headaches Dizziness Diarrhea Anxiety Extrapyramidal side effects (particularly common with first-generation antipsychotics), which include: Akathisia, an often distressing sense of inner restlessness. Dystonia, an abnormal muscle contraction Pseudoparkinsonism, symptoms that are similar to what people with Parkinson's disease experience, including tremulousness and drooling Hyperprolactinaemia (rare for those treated with clozapine, quetiapine and aripiprazole), which can cause: Galactorrhoea, the unusual secretion of breast milk. Gynaecomastia, abnormal growth of breast tissue Sexual dysfunction (in both sexes) Osteoporosis Orthostatic hypotension Weight gain (particularly prominent with clozapine, olanzapine, quetiapine and zotepine, can be counteracted by starting the drug with metformin) Antipsychotic medication-induced weight gain (AIWG) is a difficult-to-manage condition. In a meta-analysis analyzing data from 9 studies having more than 40,000 patients with AIWG, use of semaglutide was on an average was associated with 7.37kg weight loss with a good reduction in waist circumference. The occurrence of psychiatric adverse events was lower in semaglutide users.
It was described as "chemically and clinically different from any of the tranquilizers, psychic energizers or other psychotherapeutic drugs now available." During studies, chlordiazepoxide induced muscle relaxation and a quieting effect on laboratory animals like mice, rats, cats, and dogs. Fear and aggression were eliminated in much smaller doses than those necessary to produce hypnosis. Chlordiazepoxide is similar to phenobarbital in its anticonvulsant properties. However, it lacks the hypnotic effects of barbiturates. Animal tests were conducted in the Boston Zoo and the San Diego Zoo. Forty-two hospital patients admitted for acute and chronic alcoholism, and various psychoses and neuroses were treated with chlordiazepoxide. In a majority of the patients, anxiety, tension, and motor excitement were "effectively reduced." The most positive results were observed among alcoholic patients. It was reported that ulcers and dermatologic problems, both of which involved emotional factors, were reduced by chlordiazepoxide. In 1963, approval for use was given to diazepam (Valium), a "simplified" version of chlordiazepoxide, primarily to counteract anxiety symptoms. Sleep-related problems were treated with nitrazepam (Mogadon), which was introduced in 1972, temazepam (Restoril), which was introduced in 1979, and flurazepam (Dalmane), which was introduced in 1975.
Though Zuckerkandl and Pauling saw the clock as compatible with natural selection, it would later become the basis of the neutral theory of molecular evolution, in which genetic drift rather than selection is the driving force of evolution at the molecular level.
Colombia returned to CONMEBOL competition at the 1957 South American Championship in Lima, a seven-team round-robin from which Bolivia and Paraguay had withdrawn, and finished fifth with four points from six matches under coach Pedro López. Heavy defeats to Argentina (2–8) on 13 March and Brazil (0–9) on 24 March left the side with ten goals scored and 25 conceded, but two victories provided encouragement. On 17 March, Carlos Arango scored in the 28th minute to beat reigning champions Uruguay 1–0 before 50,000 spectators at the Estadio Nacional, and the campaign closed on 1 April with a 4–1 win over Ecuador in which Delio Gamboa scored twice. Arango and Gamboa finished as Colombia's joint top scorers with three goals each, while goalkeeper Efraín Sánchez and defender Francisco Zuluaga started every match after the opening fixture.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.